Lung cancer - SCLC | ApexOnco - Clinical Trials news and analysis

“It's very intuitive and always up-to-date”

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

10 September 2023

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.

Conferences Trial results

17 August 2023

Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.

Recent Quick take